Publication Detail

Citation : Shiramizu B, Goldman S, Kusao I, Agsalda M, Lynch J, Smith L, Harrison L, Morris E, Gross TG, Sanger W, Perkins S, Cairo MS. (2011)
Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: a children's oncology group report.
Br J Haematol 153(6):758-63.
Abstract : Children/adolescents with mature B-cell non-Hodgkin lymphoma (B-NHL) have an excellent prognosis but relapses still occur. While chromosomal aberrations and/or clonal immunoglobulin (Ig) gene rearrangements may indicate risk of failure, a more universal approach was developed to detect minimal disease (MD). Children/adolescents with intermediate-risk B-NHL were treated with French-British-American/Lymphome Malins de Burkitt 96 (FAB/LMB96) B4 modified chemotherapy and rituximab. Specimens from diagnosis, end of induction (EOI), and end of therapy (EOT) were assayed for MD. Initial specimens were screened for IGHV family usage with primer pools followed by individual primers to identify MD. Thirty-two diagnostic/staging specimens screened positive with primer pools and unique IGHV family primers were identified. Two patients relapsed; first relapse (4 months from diagnosis) was MD-positive at EOI, the second (36 months from diagnosis) was MD-positive at EOT. At EOI, recurrent rates were similar between the MRD-positive and MRD-negative patients (P = 0�·40). At EOT, only 13/32 patients had MRD data available with one relapse in the MRD-positive group and no recurrences in the MRD-negative group (P = 0�·077). The study demonstrated molecular-disseminated disease in which IgIGHV primer pools could be used to assess MD. This feasibility study supports future investigations to assess the validity and significance of MD screening in a larger cohort of patients with intermediate-risk mature B-NHL.
URL Link : http://www.ncbi.nlm.nih.gov/pubmed/21496005
PMID : 21496005
PMCID : PMC3103617
News
02 February 2018:
The Mary Kay Foundation - GRANT APPLICATION ANNOUNCEMENT

The Mary Kay Foundation

GRANT APPLICATION ANNOUNCEMENT

Applications are accepted from
November 2, 2017 through February 2, 2018

DEADLINE is …

08 December 2017:
F31 Award Submission Alert

The Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (F31 …

06 November 2017:
NRMN Grant Writing Coaching Group Applications

Are you preparing a proposal to submit to NIH in the upcoming months? Do you want to be coached on effective writing techniques from experienced grant…


View more news...


Seminars & Events
16 June 2017, 9am - 10:30am:
HEALTH & MEDICINE SEMINAR - Kukulu Ola Hou
02 June 2017, 8:15am - 4:10pm:
PROMOTING EXCELLENCE IN CLINICAL RESEARCH
02 November 2016, 9am:
RMATRIX-II Collaboration Pilot Projects Program 2017 -- Informational Webinar

View more seminars & events...

Supported by a grant from the National Institute on Minority Health and Health Disparities (U54MD007584), National Institutes of Health.